Skip to content

Study · Not a test of the peptide alone · 1997

1 result

Insulin-like growth factor binding protein-1 induces insulin release in the rat.

Mortensen DL, Won WB, Siu J, Reifsnyder D, Gironella M, Etcheverry T, Clark RG

Endocrinology1 May 1997Cited by 19 (Europe PMC)

PMID9112407 (opens in a new tab)DOI10.1210/endo.138.5.5143 (opens in a new tab)PepBankPUB-09112407
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism

    In normal and diabetic rats, rhIGFBP-1 pretreatment did not affect the hypoglycemic response to des(1‑3)IGF-I.

    In plain wordsIn rats, rhIGFBP-1 pretreatment did not change the blood sugar response to des(1‑3)IGF-I compared with no pretreatment.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeModification of des(1-3)IGF-I hypoglycemic response
    Study

    ratn: not reported in source

    Normal and streptozotocin-diabetic male Wistar rats
    Comparator
    No rhIGFBP-1 pretreatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    rhIGFBP-1 pretreatment, in normal and diabetic rats, reduced the hypoglycemic response to rhIGF-I (diabetic rats after 20 min: PBS, 103.4 +/- 11.4; BP-1 (500 microg) +/- rhIGF-I (50 microg), 97.6 +/- 3.6; rhIGF-I, 48.2 +/- 4.3% initial) but did not affect the hypoglycemic response to des(1-3)IGF-I o…

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.